Harrow (NASDAQ:HROW) executives used the company’s fourth-quarter 2025 earnings call to highlight what CEO Mark Baum ...
Investor's Business Daily on MSN
Why IBD stock of the day Harrow has its sights on a breakout
Harrow is Monday's IBD Stock Of The Day. The biotech stock is setting up to tack a handle onto a seven-week cup.
Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year period; Full-Year r ...
Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results